International liquid biopsy standardization alliance white paper

Connors, Dana E.; Allen, Jeff; Alvarez, Juan; Boyle, Jennifer; Cristofanilli, Massimo; Hiller, Carolyn; Keating, Susan M.; Kelloff, Gary; Leiman, Lauren C.; McCormack, Robert; Merino, Diana M.; Morgan, Emily; Pantel, Klaus; Rolfo, Christian; Serrano, María José; Sanzone, Angelo; Schlange, Thomas; Sigman, Caroline C.; Stewart, Mark

doi:10.1016/j.critrevonc.2020.103112

Cited by 75 publications

(49 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although many methods have been explored, a standardized method for EV isolation and purification is necessary. In addition, a consensus is needed on the collection and analysis of EVs from biological fluid samples [96].…”

Section: Outstanding Questionsmentioning

confidence: 99%

Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy

Zhou

et al. 2021

EBioMedicine

View full text Add to dashboard Cite

Cancer remains one of the most challenging diseases, as many patients show limited therapeutic response to treatment. Liquid biopsy is a minimally invasive method that has the advantage of providing real-time disease information with the least damage to cancer patients. Extracellular vesicles (EVs) released by the parental cells and protected by lipid bilayer membrane structure represent an emerging liquid biopsy modality. Apart from promoting cell growth, proliferation, and migration, EVs and their cargos (mainly miRNAs and proteins) are also biomarkers for cancer diagnosis and prognosis. Furthermore, their alterations pre-and post-therapy can guide therapeutic strategy determinations for better-stratified therapy. In this review, we summarize the potential clinical significance of EVs and their cargos in therapeutic response monitoring and prediction in several cancers (mainly lung cancer, prostate cancer, breast cancer, melanoma, lymphoma, glioblastoma, and head and neck squamous cell carcinoma) and discuss the questions that require future investigation.

show abstract

Section: Outstanding Questionsmentioning

confidence: 99%

Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy

Zhou

et al. 2021

EBioMedicine

View full text Add to dashboard Cite

show abstract

“…Different blood collection tubes and cfDNA isolation methods can influence the cfDNA amount and the detection of promoter methylation [82,83]. Recently, there has been an international effort to standardize liquid biopsy procedures and protocols, such as the International Liquid Biopsy Standardization Alliance (https://fnih.org/what-we-do/biomarkersconsortium/programs/ilsa)-who recently provided a white paper focused on the independent liquid biopsyand standardization-based programs [84]-the European Liquid Biopsy Society (https://www.uke.de/ english/departments-institutes/institutes/tumor-biology/ european-liquid-biopsy-society-elbs/index.html) and the International Society of Liquid Biopsy (https:// www.isliquidbiopsy.org/).…”

Section: Ctdna Methylation Assays: Standardization and Pre-analytical Considerationsmentioning

confidence: 99%

Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook

Lianidou

2021

Molecular Oncology

View full text Add to dashboard Cite

Liquid biopsy, a minimally invasive approach, is a highly powerful clinical tool for the real-time follow-up of cancer and overcomes many limitations of tissue biopsies. Epigenetic alterations have a high potential to provide a valuable source of innovative biomarkers for cancer, owing to their stability, frequency, and noninvasive accessibility in bodily fluids. Numerous DNA methylation markers are now tested in circulating tumor DNA (ctDNA) as potential biomarkers, in various types of cancer. DNA methylation in combination with liquid biopsy is very powerful in identifying circulating epigenetic biomarkers of clinical importance. Blood-based epigenetic biomarkers have a high potential for early detection of cancer since DNA methylation in plasma can be detected early during cancer pathogenesis. In this review, we summarize the latest findings on DNA methylation markers in ctDNA for early detection, prognosis, minimal residual disease, risk of relapse, treatment selection, and resistance, for breast, prostate, lung, and colorectal cancer.

show abstract

“…Multi-centric and independent validation studies need to be systematically set up to evaluate the reproducibility and the robustness of the different techniques as well as to better control the different steps of the pre-analytical phases [ 122 , 123 , 124 ]. So, a number of initiatives aimed at establishing new recommendations and guidelines have started to emerge [ 125 , 126 , 127 ].…”

Section: Ngs With Blood At Diagnosis Of Advanced Non-small Cell Lung Carcinoma: How To Optimize?mentioning

confidence: 99%

Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients

Hofman

2021

Cancers

View full text Add to dashboard Cite

Recently, the liquid biopsy (LB), a non-invasive and easy to repeat approach, has started to compete with the tissue biopsy (TB) for detection of targets for administration of therapeutic strategies for patients with advanced stages of lung cancer at tumor progression. A LB at diagnosis of late stage non-small cell lung carcinoma (NSCLC) is also being performed. It may be asked if a LB can be complementary (according to the clinical presentation or systematics) or even an alternative to a TB for treatment-naïve advanced NSCLC patients. Nucleic acid analysis with a TB by next-generation sequencing (NGS) is gradually replacing targeted sequencing methods for assessment of genomic alterations in lung cancer patients with tumor progression, but also at baseline. However, LB is still not often used in daily practice for NGS. This review addresses different aspects relating to the use of LB for NGS at diagnosis in advanced NSCLC, including its advantages and limitations.

show abstract

International liquid biopsy standardization alliance white paper

Cited by 75 publications

References 16 publications

Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy

Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy

Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook

Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients

Contact Info

Product

Resources

About